The Zhitong Finance App learned that Lepu Biology-B (02157) was active against the market at the beginning of the session, rising to HK$11.08. The import application for its CG0070 injection class 1 new drug was officially accepted. Currently, the company is starting phase I clinical trials related to CG0070 in China. As of press release, Lepu Biotech rose 18.90% to HK$994, with a turnover of HK$29 million.

Recently, CDE's official website showed that Lepu Biotech's CG0070 injection class 1 new drug import application was officially accepted. CG0070 is an oncolytic adenovirus that treats bladder cancer that has failed to be treated with BCG. Currently, Lepu Biotech has been granted the right to develop, manufacture and commercialize CG0070 in Greater China. As of June 30, 2022, phase I clinical trials are being initiated in China. Furthermore, this month, the results of a multi-center phase II clinical study of MRG003 by Lepu Biotech for the treatment of recurrent/metastatic nasopharyngeal cancer were released. Earlier, Lepu Biotech indicated that in the second half of 2022, the company will accelerate the commercialization of product pipelines, especially the MRG002 and MRG003 ADC products.